{"entity":{"id":"dat-1604","kind":"drug","name":"DAT-1604","aka":[],"tldr":"DAT-1604 is an experimental small molecule from Danatlas Pharmaceuticals, in phase 1 trials for advanced solid tumours.","summary":"DAT-1604 is a small molecule (oral tablet) from Danatlas Pharmaceuticals. A selective oral small-molecule inhibitor of DNA polymerase theta (Pol θ). Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06998173 not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Danatlas Pharmaceuticals: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06998173"},{"label":"ClinicalTrials.gov: trials of DAT-1604","url":"https://clinicaltrials.gov/search?intr=DAT-1604"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["polq"],"drugs":[],"companies":["danatlas-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06998173"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DAT-1604","modality":"Small molecule (oral tablet)","mechanism":"A selective oral small-molecule inhibitor of DNA polymerase theta (Pol θ).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dat-1604/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/"}],"company":[{"id":"danatlas-pharmaceuticals","kind":"company","name":"Danatlas Pharmaceuticals","route":"/companies/danatlas-pharmaceuticals/"}],"trial":[{"id":"nct06998173","kind":"trial","name":"Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor","route":"/trials/nct06998173/"}]}}